S&P 500 7,494 -0.65% Nasdaq 25,800 -1.18% Dow Jones 52,138 -0.71% FTSE 100 10,568 +0.37% DAX 24,936 -0.84% Nikkei 225 66,232 -2.23% Hang Seng 25,132 +3.25% WTI Crude 84.81 +7.42% Gold 4,068 +2.06% US 10-Year Treasury Yield 4.626 +1.78% S&P 500 7,494 -0.65% Nasdaq 25,800 -1.18% Dow Jones 52,138 -0.71% FTSE 100 10,568 +0.37% DAX 24,936 -0.84% Nikkei 225 66,232 -2.23% Hang Seng 25,132 +3.25% WTI Crude 84.81 +7.42% Gold 4,068 +2.06% US 10-Year Treasury Yield 4.626 +1.78%

LATEST

IMF Flags Higher Oil Price As Key Risk to India’s GDP Growth●Bets against SpaceX grow to 32% of float as Elon Musk warns short sellers won't survive●Augustus raises $180 million to build a clearing bank for the AI and stablecoin era●Oman opens renewable electricity market to direct power sales●Intuitive Surgical (ISRG) Slid Despite Strong Fundamentals●Terrorists turn to drones, cryptocurrency as Nigeria’s insurgency enters new technological phase – UN●These Dividend Aristocrats Yield Enough to Let Your Passive Income Do the Heavy Lifting●OpenAI Is on Pace to Miss Its Own Ad Revenue Forecast by 90%. Here’s What It Means For The AI Trade●IMF Flags Higher Oil Price As Key Risk to India’s GDP Growth●Bets against SpaceX grow to 32% of float as Elon Musk warns short sellers won't survive●Augustus raises $180 million to build a clearing bank for the AI and stablecoin era●Oman opens renewable electricity market to direct power sales●Intuitive Surgical (ISRG) Slid Despite Strong Fundamentals●Terrorists turn to drones, cryptocurrency as Nigeria’s insurgency enters new technological phase – UN●These Dividend Aristocrats Yield Enough to Let Your Passive Income Do the Heavy Lifting●OpenAI Is on Pace to Miss Its Own Ad Revenue Forecast by 90%. Here’s What It Means For The AI Trade●

Asia

US biotech firm developing therapies for infant brain injuries plans Hong Kong listing

Business - South China Morning Post · 3h ago · 🇨🇳 China

US biotech firm developing therapies for infant brain injuries plans Hong Kong listing

A US-headquartered biotech firm plans to seek a primary listing in Hong Kong, joining a swelling pipeline of artificial intelligence-powered medical players raising capital in the city. Axiom Biosciences, which develops experimental therapies for newborns with severe brain injuries by using AI, is targeting at least US$200 million through an initial public offering (IPO) in Hong Kong in 2027, followed by a secondary listing in the US in 2029. “Some of the most important science in the world is...

Read the full story at Business - South China Morning Post →

More Asia

Anant Raj to demerge data centre arm into separately listed company

Markets-Economic Times · 42m ago

Powerful rally! This Wall Street AI winner with 500% share price jump is not your typical chip stock

Markets-Economic Times · 51m ago

SEBI asks depositories to implement ISIN-level freeze framework for promoter holdings by Aug 1

Markets-Economic Times · 1h ago

Sebi cancels registration of 11 research analysts for non-payment of renewal fee

Markets-Economic Times · 1h ago